Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT07454135

Mechanisms of Atrial Pathoelectrophysiology in HCM

Mechanisms of Atrial Pathoelectrophysiology in HCM — Recruiting • Cardiology / Cardiovascular • NCT07454135.

📅 11 Sep 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT07454135
Sponsor
Guy's and St Thomas' NHS Foundation Trust
Start
2026-05-26
ClinicaliQ Trial Snapshot
  • Mechanisms of Atrial Pathoelectrophysiology in HCM — Recruiting • Cardiology / Cardiovascular • NCT07454135.
  • Sponsor: Guy's and St Thomas' NHS Foundation Trust.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This study aims to learn why atrial fibrillation (AF), a type of irregular heartbeat, happens more often and is harder to treat in people with hypertrophic cardiomyopathy (HCM). HCM is an inherited condition where the heart muscle is thicker than usual. Researchers will study electrical signals from the heart and advanced heart imaging. By doing this, they hope to better understand how AF behaves in people with HCM and why treatments may not work as well for them. The information from this study may help improve future treatments for people…

Eligibility Snapshot
  • : * Paroxysmal or persistent atrial fibrillation * Diagnosis of hypertrophic cardiomyopathy * Patient planning to proceed to atrial fibrillation ablation following clinical consultation * Age 18-80 years * Able and willing to provide written informed consent * Able and willing to comply with study follow up requirements

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
2024 ESC Guidelines for the Management of Atrial Fibrillation
Cardiology / Cardiovascular · 30 Mar 2026
Covers AF classification, stroke risk assessment (CHA2DS2-VASc), and bleeding risk (HAS-BLED) • Provides recommendations for rate vs rhythm control strategies • Addresses…
View guideline →
Clinical Brief
Women’s voices to be at the heart of renewed health strategy
Cardiology / Cardiovascular · NHS England · 14 Apr 2026
Women's Health Strategy will be renewed with enhanced mechanisms to centre female patient voices in healthcare planning and delivery Strategy aims to…
View brief →
Clinical Brief
Campaigners hold vigil as stroke unit closes
Cardiology / Cardiovascular · BBC Health · 10 Sep 2026
Stroke unit closure will redirect acute stroke patients to neighbouring hospitals in Taunton or Dorchester, potentially impacting treatment times and transfer protocols…
View brief →
Clinical Brief
Man completes half marathon after two heart attacks
Cardiology / Cardiovascular · BBC Health · 26 Aug 2026
Key Takeaways for Clinical Practice Cardiac rehabilitation and secondary prevention can enable significant functional recovery post-myocardial infarction, with patients potentially returning to…
View brief →
Guideline
Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction
Cardiology / Cardiovascular · 05 Aug 2026
Finerenone is recommended as an option for chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) and can be initiated…
View guideline →
Guideline
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy
Cardiology / Cardiovascular · 30 Jul 2026
Patient selection: Consider aficamten for symptomatic obstructive hypertrophic cardiomyopathy patients who remain symptomatic despite optimised standard therapy (beta-blockers, non-dihydropyridine calcium channel blockers,…
View guideline →